Become a member

Quick Registration

Full Registration Benefits -

Free Homepages for Doctors

Free Homepages for Hospitals

Free Homepages for Medical Conference

Free Homepages for NGO's

Personal Health Record Creation

Access to all Medical Slides

Access to all Jobs & Products Sale

Explore Medindia

Medindia » Press Release » Congressional Health Care Caucus Policy Forum: Biosimilars: Moving Forward Under Health Care Reform Legislation (PPACA)

Congressional Health Care Caucus Policy Forum: Biosimilars: Moving Forward Under Health Care Reform Legislation (PPACA)

7/19/2010 Indian Health News

ATTN: Healthcare Press

WHEN: TODAY, Monday, July 19 from 3 - 4 PM

WHERE: House Visitor Center Room 201 - U.S. Capitol Visitor's Center

WHO:

Hosted by Rep. Michael C. Burgess, M.D., Chairman, Congressional Health Care Caucus

Contact: Dr. Merrill Matthews Jr. at +1-972-874-5139

/PRNewswire-USNewswire -- July 19/

-- Merrill Matthews, Institute for Policy Innovation -- Dr. Craig Kessler, Professor of Medicine and Pathology, Georgetown University -- Dr. Marc Cohen, Chief of the Division of Cardiology, Newark Beth Israel Medical Center, Professor of Medicine at Mount Sinai School of Medicine in New York City

SOURCE Institute for Policy Innovation

Email

RSS Feeds

Print

Save

Link

Syndicate

Comments

New Product Planning Plays a Critical Role for Future Research & Development Success

Utah Conference 'Explosion of Youth Problems--Crisis and Solutions' to Feature News Conf w/ Atty Gen. Shurtleff, 4-Star Gen.-Fmr U.S. Drug Czar McCaffrey, CRC Health Chair Dr. Karlin, Intro by Utah First Lady Herbert: July 28 11 AM SLC Westminster Coll.

Comment & Contribute

Post your comments * Your comment can be maximum of 2500 characters
	I agree to the terms and conditions
Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished. Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.
Member Comments (1)

Biosimilars in India Though biosimilars are highly valued for their effectiveness as treatments, the costs-per-patient of many biologics are often significant and sometimes can be prohibitive. As all countries tussle with the issues of access to biologics and other medicines while confronting increasingly limited health care resources; achievement of the full potential of biosimilars is becoming increasingly challenging. My colleagues and I recently authored, What we believe to be, one of the most in-depth reports on the Biosimilars industry in India. If anyone is interested in this, feel free to write to me at infoalcpl@gmail.com. Ashritha. (Posted by infoalcpl, Date : 10/9/2010 )